[go: up one dir, main page]

PE20091960A1 - Compuestos de insulina lispro pegilada - Google Patents

Compuestos de insulina lispro pegilada

Info

Publication number
PE20091960A1
PE20091960A1 PE2009000763A PE2009000763A PE20091960A1 PE 20091960 A1 PE20091960 A1 PE 20091960A1 PE 2009000763 A PE2009000763 A PE 2009000763A PE 2009000763 A PE2009000763 A PE 2009000763A PE 20091960 A1 PE20091960 A1 PE 20091960A1
Authority
PE
Peru
Prior art keywords
lispro
insulin
pegilated
amino group
kda
Prior art date
Application number
PE2009000763A
Other languages
English (en)
Inventor
John Michael Beals
Gordon Butler Cuttler Jr
Ryan John Hansen
Shun Li
Lianshan Zhang
Brandon Doyle
Shahriar Shirani
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41110836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091960(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20091960A1 publication Critical patent/PE20091960A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN COMPUESTO DE INSULINA LISPRO PEGILADA DE FORMULA: P-[(A)-(B)] O UNA SAL DEL MISMO DONDE A ES LA CADENA A DE INSULINA LISPRO (SEC ID NO:1), B ES LA CADENA B DE INSULINA LISPRO (SEC ID NO:3) Y P ES UN POLIETILENGLICOL QUE TIENE UN PESO MOLECULAR DE 20 Kda A 40 Kda Y ESTA UNIDO VIA UN ENLACE COVALENTE DE URETANO O TIOETER AL GRUPO ALFA-AMINO DE LA GlICINA EN LA POSICION 1 DE A, EL GRUPO AFA-AMINO DE LA FENILALANINA EN LA POSICION 1 DE B, O EL GRUPO EPSILON-AMINO DE LA LISINA EN LA POSICION 28 DE B. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO, UN AMORTIGUADOR TRIS, 130 mM DE M-CRESOL, ZINC, Zn, DE 100 mM A 150 mM DE NaCl, DE 2,5 A 25 Mm DE CALCIO Y UN TENSOACTIVO. DICHA INSULINA ES UTIL EN EL TRATAMIENTO LA HIPERGLICEMIA O DIABETES
PE2009000763A 2008-06-13 2009-06-02 Compuestos de insulina lispro pegilada PE20091960A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6128108P 2008-06-13 2008-06-13
US12139408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
PE20091960A1 true PE20091960A1 (es) 2010-01-15

Family

ID=41110836

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009000763A PE20091960A1 (es) 2008-06-13 2009-06-02 Compuestos de insulina lispro pegilada
PE2014000431A PE20140974A1 (es) 2008-06-13 2009-06-02 Compuestos de insulina lispro pegilada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000431A PE20140974A1 (es) 2008-06-13 2009-06-02 Compuestos de insulina lispro pegilada

Country Status (33)

Country Link
US (3) US20110105392A1 (es)
EP (2) EP2288375B1 (es)
JP (2) JP4890662B2 (es)
KR (1) KR101238979B1 (es)
CN (1) CN102065884B (es)
AR (1) AR071990A1 (es)
AT (1) ATE554786T1 (es)
AU (1) AU2009257597B2 (es)
BR (1) BRPI0915838A2 (es)
CA (1) CA2727825C (es)
CL (1) CL2009001340A1 (es)
CO (1) CO6331292A2 (es)
CY (2) CY1112977T1 (es)
DK (2) DK2476430T3 (es)
DO (1) DOP2010000379A (es)
EA (1) EA028657B1 (es)
EC (1) ECSP10010677A (es)
ES (2) ES2383496T3 (es)
HR (2) HRP20120397T1 (es)
IL (1) IL209265A (es)
JO (1) JO2932B1 (es)
MA (1) MA32394B1 (es)
MX (1) MX2010013837A (es)
MY (1) MY158890A (es)
NZ (1) NZ588997A (es)
PE (2) PE20091960A1 (es)
PL (2) PL2288375T3 (es)
PT (2) PT2476430E (es)
RS (1) RS52361B (es)
SI (2) SI2288375T1 (es)
TW (1) TWI451876B (es)
WO (1) WO2009152128A1 (es)
ZA (1) ZA201008174B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR20110085985A (ko) * 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
BR112012028766A2 (pt) * 2010-05-10 2017-06-13 Novo Nordisk As processo para a preparação de complexos de insulina e zinco
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
EP2571516B1 (en) * 2010-05-18 2017-11-15 Neumedicines, Inc Il-12 formulations for enhancing hematopoiesis
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011257219B2 (en) * 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2821411C (en) 2010-12-13 2020-02-25 Marek Kwiatkowski Functionalized polymers
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012165916A2 (en) 2011-06-02 2012-12-06 Hanmi Science Co., Ltd. Non-peptidyl polymer-insulin multimer and method for producing the same
WO2012174478A2 (en) * 2011-06-17 2012-12-20 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
CA2843586A1 (fr) * 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
HRP20151068T1 (hr) 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HK1206779A1 (en) 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AR090843A1 (es) 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
WO2013186632A2 (en) 2012-06-12 2013-12-19 Quiapeg Ab Conjugates of biologically active molecules to functionalized polymers
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
IN2015DN00544A (es) 2012-07-23 2015-06-26 Zealand Pharma As
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP6322642B2 (ja) * 2012-11-13 2018-05-09 アドシア 置換されたアニオン性化合物を含有する速効型インスリン製剤
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
WO2014099577A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014247167B2 (en) 2013-04-03 2018-11-22 Sanofi Treatment of diabetes mellitus by long–acting formulations of insulins
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2688708T3 (es) 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105092490B (zh) * 2014-05-04 2019-08-09 重庆派金生物科技有限公司 人胰岛素及类似物或偶联物体外生物活性测定方法
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AR107560A1 (es) 2016-02-24 2018-05-09 Lilly Co Eli Compuesto que disminuye la glucosa en la sangre
HUE060149T2 (hu) 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
US20180236080A1 (en) * 2017-02-22 2018-08-23 Adocia Fast-acting insulin composition comprising a citric acid salt
SI3592393T1 (sl) 2017-03-10 2022-04-29 Quiapeg Pharmaceuticals Ab Sprostljivi konjugati
IL270975B2 (en) * 2017-06-01 2024-02-01 Lilly Co Eli Fast-acting insulin preparations
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
FR3084585B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
CA3113651A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
EP4072577A4 (en) * 2019-12-13 2024-02-14 The Board of Trustees of the Leland Stanford Junior University STABLE MONOMERIC INSULIN FORMULATIONS BY SUPRAMOLECULAR PEGYLATION OF INSULIN ANALOGS
CN113801236A (zh) * 2020-06-11 2021-12-17 宁波鲲鹏生物科技有限公司 一种赖脯胰岛素的制备方法
AU2023272483A1 (en) 2022-05-18 2024-12-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ223630A (en) 1987-02-25 1989-11-28 Novo Industri As Insulin derivative and pharmaceutical compositions
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
HU217684B (hu) 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EP1044016B1 (en) 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
PT1121144E (pt) * 1998-10-16 2002-11-29 Novo Nordisk As Preparados de insulina concentrada estavel para administracao pulmonar
US6734162B2 (en) * 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
BR0209896A (pt) * 2001-05-21 2004-08-17 Nektar Therapeutics Composição de insulina para administração pulmonar, e, métodos para suprir insulina a um indivìduo mamìfero, para prover uma composição de insulina não-imunogênica e uma composição de insulina de efeito prolongado para administração ao pulmão de um indivìduo
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
SK2432004A3 (sk) * 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
WO2004089280A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
EP1613272B1 (en) 2003-04-11 2013-12-18 Antriabio, Inc. Method for preparation of site-specific protein conjugates
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
US20060045866A1 (en) 2004-09-01 2006-03-02 Chris Chappelow Novel high purity and high molecular weight mPEG alcohol compositions
US7199193B2 (en) 2004-09-28 2007-04-03 Dow Global Technologies, Inc. Polyethylene glycol compounds and process of making
CN100540565C (zh) * 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 修饰的Exendins及其应用
EP1843790A2 (en) * 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
US7824919B2 (en) 2005-03-04 2010-11-02 Dr. Reddy's Laboratories Limited Method for analyzing activated polyethylene glycol compounds
EP1863840A1 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
AU2006247734B2 (en) * 2005-05-13 2011-06-23 Eli Lilly And Company GLP-1 pegylated compounds
JP5096363B2 (ja) * 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
WO2008084051A1 (en) 2007-01-12 2008-07-17 Novo Nordisk A/S Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物

Also Published As

Publication number Publication date
CA2727825A1 (en) 2009-12-17
IL209265A0 (en) 2011-01-31
AR071990A1 (es) 2010-07-28
NZ588997A (en) 2012-03-30
JP2012092124A (ja) 2012-05-17
EP2288375A1 (en) 2011-03-02
CO6331292A2 (es) 2011-10-20
US20110105392A1 (en) 2011-05-05
US20090312236A1 (en) 2009-12-17
EP2288375B1 (en) 2012-04-25
WO2009152128A1 (en) 2009-12-17
EP2476430B1 (en) 2014-05-14
MA32394B1 (fr) 2011-06-01
RS52361B (sr) 2012-12-31
US9050371B2 (en) 2015-06-09
JP5336572B2 (ja) 2013-11-06
CY1112977T1 (el) 2016-04-13
SI2288375T1 (sl) 2012-07-31
ECSP10010677A (es) 2011-01-31
MY158890A (en) 2016-11-30
TW201010728A (en) 2010-03-16
CA2727825C (en) 2014-10-21
EA201170020A1 (ru) 2011-10-31
ZA201008174B (en) 2012-04-25
IL209265A (en) 2014-08-31
BRPI0915838A2 (pt) 2015-11-03
ATE554786T1 (de) 2012-05-15
JP2011524357A (ja) 2011-09-01
HK1170659A1 (en) 2013-03-08
CN102065884B (zh) 2014-11-05
PE20140974A1 (es) 2014-08-25
DOP2010000379A (es) 2011-03-31
EA028657B1 (ru) 2017-12-29
MX2010013837A (es) 2011-05-03
AU2009257597A8 (en) 2011-01-06
PT2476430E (pt) 2014-07-25
HRP20140480T1 (hr) 2014-07-04
ES2473580T3 (es) 2014-07-07
AU2009257597B2 (en) 2011-10-06
TWI451876B (zh) 2014-09-11
US20150297681A1 (en) 2015-10-22
JO2932B1 (en) 2015-09-15
CN102065884A (zh) 2011-05-18
PL2288375T3 (pl) 2012-09-28
HRP20120397T1 (hr) 2012-06-30
DK2476430T3 (da) 2014-06-02
DK2288375T3 (da) 2012-05-21
CY1115354T1 (el) 2017-01-04
ES2383496T3 (es) 2012-06-21
PT2288375E (pt) 2012-05-17
CL2009001340A1 (es) 2010-06-04
EP2476430A1 (en) 2012-07-18
PL2476430T3 (pl) 2014-09-30
AU2009257597A1 (en) 2009-12-17
KR101238979B1 (ko) 2013-03-05
JP4890662B2 (ja) 2012-03-07
KR20110017879A (ko) 2011-02-22
HK1149713A1 (en) 2011-10-14
SI2476430T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
PE20091960A1 (es) Compuestos de insulina lispro pegilada
AR117403A2 (es) Formulaciones de anticuerpos
PE20141413A1 (es) Formulaciones de anticuerpo y metodos
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
NZ629204A (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
CY1117363T1 (el) Σκευασμα αντισωματος κατα abeta
AR109135A2 (es) Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv
EA201992304A1 (ru) Пептид, обладающий цитопротекторным эффектом против действия загрязняющих окружающую среду веществ, и его применение
PE20171512A1 (es) Anticuerpos anti-fap
PE20081043A1 (es) Composicion farmaceutica que comprende bifosfonatos
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
NZ705178A (en) Anti-prolactin receptor antibody formulations
MX347600B (es) Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos.
GT200900019A (es) Compuestos organicos
GT200600136A (es) Heteroarilamidas [3.1.0] biciclicas como inhibidores del transporte de glicina de tipo i
CO6612278A2 (es) Composición acuosa antitranspirante/desodorante
AR091567A1 (es) Preparacion liquida, metodo, kit de inyeccion
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
PE20141473A1 (es) Senalizacion slit-robo para el diagnostico y tratamiento de la enfermedad renal
PE20131316A1 (es) Composiciones para el tratamiento de plantas y metodos para su uso
UA100255C2 (uk) Фармацевтична композиція
MX342712B (es) Macromolecula para el suministro de farmacos de proteina, polipeptido o peptido y un metodo de produccion para la misma, y una composicion de liberacion lenta para farmacos de proteina, polipeptido o peptido y un metodo de produccion para la misma.

Legal Events

Date Code Title Description
FC Refusal